The newly public AbbVie's dividend will be too concentrated to a single drug, while the payout from the remaining Abbott entity won't be as generous as in years past, according to Morningstar's Josh Peters.
Compared with other investments, the income consistency that dividends provide on a pretax basis allows them to retain their value and practicality even if tax rates increase, says Morningstar's Josh Peters.
Since the taper talks began, conditions have improved for dividend investors, who can now buy quality names without being vulnerable to long -term interest-rate spikes, says DividendInvestor editor Josh Peters.
This article represents opinions of the author and not those of his firm and are subject to change from time to time and do not constitute a recommendation to purchase and sale any security nor to engage in any particular investment strategy. The information contained here has been obtained from ...